Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - What's Next?

Key Points

• Shares passed below its 200-day moving average: NWBO fell beneath the $0.24 200-day MA, trading as low as $0.1921 and last at $0.1948 on heavy volume (10,362,756 shares) and was down about 3.9%.
• Clinical-stage biotech with a lead Phase III program: Northwest Biotherapeutics develops personalized dendritic cell immunotherapies, with lead candidate DCVax‑L targeting newly diagnosed or recurrent glioblastoma multiforme and a market cap of about $317.5 million while remaining unprofitable (negative P/E).

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.24 and traded as low as $0.1921. Northwest Biotherapeutics shares last traded at $0.1948, with a volume of 10,362,756 shares traded.

Northwest Biotherapeutics Stock Down 3.9%

The company has a market cap of $317.52 million, a price-to-earnings ratio of -0.01 and a beta of -0.77. The stock has a 50 day simple moving average of $0.21 and a 200 day simple moving average of $0.24.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company's proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient's tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company's lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.